The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,346K data for 622K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

23 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of a novel Kv7 channel opener as a treatment for epilepsy.EBI
Pfizer
Potent and selective inhibitors of the TASK-1 potassium channel through chemical optimization of a bis-amide scaffold.EBI
University Of Kansas Specialized Chemistry Center
Ion channels as therapeutic targets: a drug discovery perspective.EBI
Pfizer
Novel KCNQ2/Q3 agonists as potential therapeutics for epilepsy and neuropathic pain.EBI
Icagen
Discovery of a series of 2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)acetamides as novel molecular switches that modulate modes of K(v)7.2 (KCNQ2) channel pharmacology: identification of (S)-2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide (ML252) as a potent, brain penetrant K(v)7.2 channel inhibitor.EBI
Vanderbilt University Medical Center
3-Oxoisoindoline-1-carboxamides: potent, state-dependent blockers of voltage-gated sodium channel Na(V)1.7 with efficacy in rat pain models.EBI
Astrazeneca
Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective K(v)7.1 (KCNQ1) potassium channel activator.EBI
Vanderbilt University Medical Center
N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy.EBI
TBA
A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.EBI
Abbott Laboratories
Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Design, synthesis and biological activity of pyrazolo[1,5-a]pyrimidin-7(4H)-ones as novel Kv7/KCNQ potassium channel activators.EBI
Hebei Medical University
Subtype-selective Na(v)1.8 sodium channel blockers: identification of potent, orally active nicotinamide derivatives.EBI
Abbott Laboratories
(S)-N-[1-(3-morpholin-4-ylphenyl)ethyl]- 3-phenylacrylamide: an orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraine.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Synthesis and Optimization of KEBI
University Of Pittsburgh
An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders.EBI
Marquette University
Synthesis and Pharmacological Characterization of Conformationally Restricted Retigabine Analogues as Novel Neuronal Kv7 Channel Activators.EBI
University Federico Ii Of Naples
Design and evaluation of pyrazolopyrimidines as KCNQ channel modulators.EBI
Abbvie
Potassium channel modulators as possible treatment for pain: patent highlight.EBI
Therachem Research Medilab (India)
Kv7 (KCNQ) channel modulators and neuropathic pain.EBI
Neurosearch
Novel KEBI
Glaxosmithkline
Design, synthesis and evaluation of novel N-phenylbutanamide derivatives as KCNQ openers for the treatment of epilepsy.EBI
Nanjing University Of Technology
Design, synthesis and evaluation of substituted piperidine based KCNQ openers as novel antiepileptic agents.EBI
Nanjing University Of Technology
Discovery of a Series of Indazole TRPA1 Antagonists.EBI
Pfizer